Similar to Galectin-3, the ACC/AHA guidelines recommend measuring sST2 for the prognostic evaluation of chronic HF patients [15], while the ESC guidelines do not endorse its use due to insufficient evidence [16]. This evidence concerns the gene LGALS3 and hydrops fetalis.